| Date | Title | Description |
| 07.04.2026 | Corporate Vision and Trade Confrontation: The Shifting U.S. Economic Narrative | Motorola Solutions CEO Greg Brown earns top honors, lauded for transforming the company into a global public safety and security technology leader. His strategic vision and operational prowess drove exceptional growth and innovation. Meanwh... |
| 06.04.2026 | Biotech Firm Gets a New Leader
New chief chosen | - |
| 02.04.2026 | Trump unveils 100% tariff on some patented drugs on ‘Liberation Day’ anniversary | Getting your Trinity Audio player ready...
By WYATTE GRANTHAM-PHILIPS, AP Business Writer
NEW YORK (AP) — President Donald Trump signed an executive order Thursday that could slap long-threatened pharmaceutical tariffs of up to 100% on some... |
| 30.03.2026 | Harbour BioMed Reports Full Year 2025 Financial Results: Sustained Global Collaboration Underpins Long-Term Growth | CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, March 30, 2026 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of... |
| 19.03.2026 | Harbour BioMed Appoints Dr. Jenny Xie as Chief Scientific Officer, Immunology and Head of Global External Innovation | CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, March 19, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody thera... |
| 10.03.2026 | Bright spots in tackling AMRs, but drug-resistance outpaces pharma industry efforts: Report | - |
| 02.03.2026 | Canva Forges Ahead Amidst AI Market Shift | Canva navigates a challenging software market. Wall Street punishes tech stocks. AI concerns drive investor apprehension. Major competitor Adobe faces significant stock declines. Canva responds with strategic acquisitions. It buys Cavalry, ... |
| 27.02.2026 | Gilead Dominates Cell Therapy: $7.8 Billion Arcellx Acquisition Seals Future | Gilead Sciences acquired Arcellx for up to $7.8 billion. This landmark acquisition secures full control of anito-cel, a potentially transformative BCMA-directed CAR T-cell therapy for relapsed or refractory multiple myeloma. Anito-cel await... |
| 27.02.2026 | Prothena Announces up to $100 Million Share Repurchase Plan | Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that its Board of Directors has authorized ... |
| 26.02.2026 | NYSE Content Update: 'Patty' at Center of Burger King's New BK Assistant AI Solution | NYSE issues a pre-market daily advisory direct from the trading floor.
NEW YORK, Feb. 26, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE P... |
| 25.02.2026 | NYSE Content Update: Two MSCI Indexes to Begin Trading on NYSE Arca Options | NYSE issues a pre-market daily advisory direct from the trading floor.
NEW YORK, Feb. 25, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE P... |
| 23.02.2026 | Prothena Reports Fourth Quarter and Full Year 2025 Financial Results, and Provides Financial Guidance and Business Highlights | Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today reported financial results for the fourth quarter and... |
| 23.02.2026 | Фармгигант из США Gilead заплатит до $7,8 млрд за разработчика CAR-T - терапии Arcellx | Gilead покупает разработчика противораковых препаратов Arcellx за сумму до $7,8 млрд. Gilead согласилась приобрести Arcellx в сделке стоимостью $7,8 млрд, поскольку фармкомпания стремится добавить в свой портфель CAR-T-клеточную терапию про... |
| 20.02.2026 | With Trump’s ‘reciprocal’ tariffs struck down, here are the industries still facing higher rates | President Donald Trump’s so-called reciprocal tariffs were deemed unconstitutional by the Supreme Court, but some sector-specific tariffs will remain in place.
The Supreme Court ruling covered IEEPA tariffs, used for national emergencies ou... |
| 20.02.2026 | Curt Smith: Fighting blood cancer is easier with a group effort | - |
| 17.02.2026 | To the shareholders of H. Lundbeck A/S | To the shareholders of H. Lundbeck A/S
Tue, Feb 17, 2026 10:00 CET Report this content NOTICE OF ANNUAL GENERAL MEETING
Notice is hereby given of the annual general meeting of H. Lundbeck A/S to be held on: WEDNESDAY, 18 MARCH 2026 AT 10:00... |
| 11.02.2026 | Will Alphabet’s century bond start a new trend? A brief history | This week Google owner Alphabet raised £1bn in a highly unusual century bond, in a sign of the extreme lengths tech firms are willing to go to to meet the ballooning capital costs of investment in AI.
The 100 year sterling note formed part ... |
| 10.02.2026 | Final Results | Final Results
Tue, Feb 10, 2026 08:00 CET Report this content
10 February 2026
AstraZeneca results: FY and Q4 2025
Strong commercial performance and excellent pipeline delivery in a continuing catalyst-rich period
Revenue and EPS summary
FY... |
| 06.02.2026 | PDA Introduces the 2026 Board of Directors and Officers | PDA's diverse Board of Directors brings a diverse set of interests, expertise, and experiences.
BETHESDA, Md., Feb. 6, 2026 /PRNewswire-PRWeb/ -- PDA is excited to introduce the all-volunteer 2026 Board of Directors and Officers following f... |
| 06.02.2026 | Cramer calls this drug maker the ‘greatest growth stock.’ He also names a runner-up | - |
| 06.02.2026 | Insilico Medicine Appoints Halle Zhang, PhD (Med), as Vice President, Clinical Development - Oncology | CAMBRIDGE, Mass., Feb. 6, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico") (3696.HK), a clinical-stage biotechnology company powered by generative artificial intelligence (AI), today announced the appointment of Halle Zhang, Ph... |
| 05.02.2026 | Providence Therapeutics Announces Appointment of Leah Goodman to the Board of Directors | Leah Goodman brings a wealth of policy and regulatory experience and is a recognized leader in Australia for advancing scientific discoveries to patient impacts.
CALGARY, AB and BRISBANE, Australia, Feb. 5, 2026 /PRNewswire/ -- Providence T... |
| 04.02.2026 | Harbour BioMed Announces Positive Profit Alert for 2025 Annual Results | CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Feb. 4, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therape... |
| 29.01.2026 | Cellares: $257 Million Series D Closed To Scale Automated Cell Therapy Manufacturing | Cellares has raised $257 million in a Series D financing co-led by investment funds managed by BlackRock and Eclipse, bringing total capital raised to $612 million. The round brings in a slate of new investors, including accounts advised by... |
| 27.01.2026 | Trialbee to Share Vision for the Last Mile of Patient Recruitment with Expert Panel, AI Innovation, and Community Collaboration at SCOPE Summit 2026 | Featuring panelists from BMS, Biogen, and Johnson & Johnson along with the Honey Platform™ and Swedish Fika Time at Booth #706
MALMÖ, Sweden and WILMINGTON, Del., Jan. 27, 2026 /PRNewswire-PRWeb/ -- Trialbee, a global leader in technolo... |
| 26.01.2026 | [Opinion] 2026: The Dawn of AI-Driven Drug Development | (Yicai) Jan. 23 -- The next big leap for artificial intelligence in healthcare is no longer in the lab, but in clinical trials -- where drug development succeeds or fails.
For years, the conversation around AI in healthcare has been dominat... |
| 24.01.2026 | Heart Attack Survivor and Social Media Powerhouse Dr. ShantaQuilette Carter-Williams to Take Center Stage at WomenHeart's 2026 Summit | WomenHeart has announced its 2026 Summit taking place February 1-3 at the Hilton Washington DC National Mall, The Wharf. Heart attack and stroke survivor Dr. ShantaQuilette Carter-Williams, a social media powerhouse with millions of followe... |
| 23.01.2026 | NVIDIA и Eli Lilly вложат $1 млрд в ИИ-лабораторию лекарств | NVIDIA и фармацевтический гигант Eli Lilly объявили о создании совместной ИИ-лаборатории с инвестициями до $1 млрд на пять лет. Лаборатория расположится в Сан-Франциско и объединит биологов и химиков Lilly с инженерами NVIDIA для круглосуто... |
| 22.01.2026 | Telangana (India) Sets Global Ambition with Next-Gen Life Sciences Policy 2026-30 | Positioning Telangana among the world's top five life sciences clusters by 2030
Targets USD 25 billion in investments
Shifts focus from scale-led manufacturing to innovation-driven, value creation
DAVOS, Switzerland, Jan. 22, 2026 /PRNewswi... |
| 21.01.2026 | Syngene International extends long-term research collaboration with Bristol Myers Squibb until 2035 | BENGALURU, India, Jan. 21, 2026 /PRNewswire/ -- Syngene International, a global contract research, development, and manufacturing organization (CRDMO), today announced the extension of its long-standing strategic collaboration with Bristol ... |
| 20.01.2026 | Another alliance of health care and AI signals why pharma stocks should be back in favor | - |
| 20.01.2026 | Drug pricing, patent losses and deals: Here’s what pharma execs see ahead in the industry | Drug pricing, looming patent cliffs, dealmaking and the first year of the second Trump administration dominated conversations at the annual JPMorgan Healthcare Conference in San Francisco.
Top executives from drugmakers of all sizes met wit... |
| 17.01.2026 | Proxima Secures $80M Seed Round to Redefine Drug Discovery | Proxima, an AI-native biotech firm, secured an $80 million seed funding round. DCVC led the investment. NVentures and other major investors participated. Formerly VantAI, the company now targets proximity therapeutics. It aims to revolution... |
| 14.01.2026 | Oramed And Lifeward Reveal Strategic Deal | Oramed Pharmaceuticals and Lifeward said they have signed binding agreements for a strategic transaction that will move Oramed’s Protein Oral Delivery platform (POD technology) to Lifeward while positioning Oramed as a major shareholder in ... |
| 14.01.2026 | Proxima: $80 Million Raised To Power The Next Generation Of Proximity-Based Medicines | Proxima, the AI-native biotech company developing drug discovery tools and therapeutics for proximity-based medicines, has raised an oversubscribed $80 million seed round and rebranded from VantAI as it sharpens its focus on proximity thera... |
| 13.01.2026 | Proxima Raises $80M in Seed Funding | Proxima (formerly VantAI), a NYC-based AI-native biotech company developing AI-driven drug discovery for proximity therapeutics, raised $80M in Seed funding.
The round was led by DCVC, with participation from NVentures (NVIDIA’s venture cap... |
| 12.01.2026 | Zydus can sell anti-cancer drug Nivolumab biosimilar in India, says Delhi high court | - |
| 07.01.2026 | Big Pharma race to snap up biotech assets as $170 billion patent cliff looms | Some of the best-selling drugs in the world are facing a loss of exclusivity in key jurisdictions in the upcoming years in what the sector calls “the patent cliff.”
The need for pharma to top up their pipelines coincides with the broader bi... |
| 06.01.2026 | Clarivate Identifies Eleven Potential Blockbuster and Transformative Therapies in its 2026 Drugs to Watch Report | Anticipated advancements in weight loss, diabetes, oncology, rare conditions and protein degraders poised to reshape patient care
LONDON, Jan. 6, 2026 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative i... |
| 03.01.2026 | Grok 4 лидирует в бенчмарке по торговле акциями: +5,7% за пять недель | В бенчмарке AI Arena от Rallies в лидеры вышел Grok 4 с концентрированным портфелем из двух акций и доходностью +5,7% за месяц с небольшим (бенчмарк стартовал 27 ноября). На противоположном полюсе — Qwen 3, потерявший почти 16%, поставив ве... |
| 21.12.2025 | Трамп договорился с фармакомпаниями о снижении цен на лекарства для хронических болезней | - |
| 20.12.2025 | US Drug Prices Face Seismic Shift: Pharma Giants Negotiate Deep Cuts | The American healthcare landscape is transforming. US drug prices, long the world's highest, face unprecedented pressure. President Trump drove an aggressive campaign to lower prescription costs. His administration pushed the Most Favored N... |
| 19.12.2025 | Trump announces lower drug price deals with 9 pharmaceutical companies | Getting your Trinity Audio player ready...
By SALLY HO
U.S. President Donald Trump announced Friday that nine drugmakers have agreed to lower the cost of their prescription drugs in the U.S. Related Articles
Michael Jackson, Diana Ross and ... |
| 19.12.2025 | Takeda Rises After AI-Developed Psoriasis Pill Trial Success | - |
| 19.12.2025 | Nine of the largest pharma companies ink deals with Trump to lower drug prices | Several of the largest U.S. and European-based drugmakers inked deals with President Donald Trump to voluntarily sell their medications for less, as his administration pushes to link the nation’s drug prices to cheaper ones abroad.
Pfizer, ... |
| 15.12.2025 | Нобелевская премия-2025: кто главные бенефициары научных открытий ученых-лауреатов? | Нобелевскую премию вручают за самые передовые открытия — и, конечно, у них есть большой коммерческий потенциал. Право авторства и право на саму разработку — это несколько разные вещи, и возможность получить действительно высокую прибыль буд... |
| 12.12.2025 | Болезням прописали инструкцию | - |
| 11.12.2025 | Indiana couple accused of insider trading on $3.7B acquisition | Please subscribe to IBJ to decode this article.
irtfa2ilrnrnsti g.ct aerc3 ituwip feooud rsnicu2rfasli s r einhen rnuilfaoi$safIno eAf ml d eiaehaa dnmg ftleagmberueo 2roe mirolyoifncd dgsca o e ohin.eifim0d ydnt rat 7nqrlbals eiloetrenacpd... |
| 01.12.2025 | UK and US agree to zero tariff deal on pharmaceuticals | The government has agreed to a major deal with Washington that will see the UK become the only country to secure zero import tariffs on pharmaceutical products into the US for at least three years.
The deal follows months of negotiations be... |
| 21.11.2025 | The Melanoma Research Foundation Launches its Inaugural Tampa Bay 5K Fundraiser with a Goal of $30,000 in Support of its Mission | The Melanoma Research Foundation (MRF) is thrilled to announce one of the next events in its annual Miles for Melanoma nationwide 5K program, bringing together local melanoma patients, supporters, caregivers and thrivers. This year we will ... |
| 13.11.2025 | John Apathy Joins DataJoint as Strategic Advisor, Strengthening Data and AI Leadership in Life Sciences R&D | , a leading informatics platform revolutionizing data management and analysis in scientific research and the life sciences sector, announced the appointment of John Apathy as a Strategic Advisor, deepening the company’s expertise in data-dr... |
| 12.11.2025 | Theo Ai Raises Over $10M in Total Funding | Theo Ai, a Palo Alto, CA-based provider of an AI-driven prediction platform for Am Law 200 and General Counsels, raised over $10M in total funding.
The latest round was led by Run Ventures.
The company intends to use the funds to accelerate... |
| 12.11.2025 | Theo Ai Announces General Counsel Advisory Board and New Funding Round Led by Run Ventures | , the AI-driven prediction platform for Am Law 200 and General Counsels, announced the formation of its General Counsel Advisory Board and a new round of funding led by Run Ventures, bringing the company’s total funding to date to over $10 ... |
| 12.11.2025 | Theo Ai Expands Predictive Legal Platform With New Funding And General Counsel Advisory Board | Theo Ai (see Pulse 2.0 profile here), an AI-driven prediction platform for Am Law 200 firms and General Counsels, announced the formation of its General Counsel Advisory Board alongside a new funding round led by Run Ventures, bringing its ... |
| 10.11.2025 |
Cramer’s Lightning Round: ‘Baidu and Alibaba are good’ | Monday - Friday, 6:00 - 7:00 PM ET
It’s that time again! “Mad Money” host Jim Cramer rings the lightning round bell, which means he’s giving his answers to callers’ stock questions at rapid speed.
Bristol-Myers Squibb: “I’m backing off on i... |
| 06.11.2025 | Prothena Reports Third Quarter 2025 Financial Results and Business Highlights | Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today reported financial results for the third quarter and ... |
| 04.11.2025 | Pfizer tops estimates, raises profit guidance even as sales fall | Pfizer reported third-quarter earnings and revenue that topped estimates and hiked its full-year profit outlook as it cuts costs, even as sales for the period fell.
The pharmaceutical giant now expects its full-year adjusted profit to come ... |
| 03.11.2025 | The Billion-Dollar Biology of Oncology: What Really Drives Pharma’s Appetite? | By Jonathan Tobin, Partner – Brandon Capital
Plenty is written about the trends in dollars and modalities being invested in oncology by VCs. But equally important are the exits, and for early-stage investors M&A is especially important.... |
| 30.10.2025 | Innovent’s tie-up with Takeda tests investor faith in China’s biotech dream | Since early October, shares of China’s innovative drugmakers have trended downward. As investors quipped about the need for another major deal to restore confidence, one such event finally arrived.
On October 22, Innovent Biologics announce... |
| 30.10.2025 | Here’s why Bristol Myers quarter wasn’t enough to change our view on the stock | - |
| 28.10.2025 |
Cytokinetics has been on a tear as the biotech pioneers more drugs to fight heart ailments | Monday - Friday, 2:00 - 3:00 PM ET
Investors are noticing ripe opportunity in Cytokinetics, a late-stage biopharma company targeting medicines for specialty heart diseases, that has seen shares skyrocket in recent months.
Shares of Cytokine... |
| 24.10.2025 | Pfizer and BioNTech Receive Health Sciences Authority Approval for SARS-CoV-2 Sublineage LP.8.1-Adapted Monovalent COVID-19 Vaccine in Singapore | The updated COVID-19 vaccine is expected to be available in Singapore at selected polyclinics and private general practitioner (GP) clinics in October 2025 for individuals 6 months of age and older.
SINGAPORE, Oct. 24, 2025 /PRNewswire/ -- ... |
| 24.10.2025 | Global Launch Event for iza-bren Phase III Nasopharyngeal Carcinoma Research Results Successfully Held, Streamed on ESMO Official Website | SHANGHAI, Oct. 24, 2025 /PRNewswire/ -- At 15:00 Beijing Time (09:00 am Berlin Time) on October 20, the "Global Launch Event for Iza-bren (EGFR×HER3 Bispecific ADC) Nasopharyngeal Carcinoma BL-B01D1-303 Research Results" was held ... |
| 23.10.2025 | Rescale Expands Digital Engineering Platform with the Launch of Data Intelligence for the AI Era | New engineering data intelligence capabilities unlock R&D knowledge to boost efficiency and accelerate innovation.
SAN FRANCISCO, Oct. 23, 2025 /PRNewswire/ -- Rescale, a digital engineering platform built for the AI era, announces the ... |
| 22.10.2025 | Largest Milestone Payment Secured: Biokin, a Rising Chinese Pharmaceutical MNC | BEIJING, Oct. 22, 2025 /PRNewswire/ -- In October 2025, a partnership between Biokin—a rising star in China's innovative pharmaceutical sector—and global pharmaceutical leader BMS triggered a $250 million milestone payment. This is believed... |
| 20.10.2025 | Positive CHMP opinion for subcutaneous Saphnelo | Positive CHMP opinion for subcutaneous Saphnelo
Mon, Oct 20, 2025 08:00 CET Report this content
20 October 2025
Saphnelo subcutaneous self-administration recommended for approval in EU by CHMP for systemic lupus erythematosus
Recommendation... |
| 13.10.2025 | Американская фармкомпания Bristol Myers покупает Orbital Therapeutics за $1,5 млрд | Сделка расширяет портфель CAR T-клеточных иммунотерапий Bristol Myers за счет ведущего экспериментального препарата Orbital — OTX-201, предназначенного для лечения аутоиммунных заболеваний. Это первое крупное приобретение компании в этом го... |
| 03.10.2025 | Drug Price Revolution: Pfizer Deal Ignites Market, Reshapes Industry | A landmark Pfizer deal with the Trump administration significantly alters US drug pricing. The agreement promises lower Medicaid costs and 'most-favored nation' launch pricing for new pharmaceuticals, ensuring Americans pay no more than oth... |
| 01.10.2025 | Trump’s pharmaceutical tariff threat loses bite after Pfizer deal reassures drugmakers | President Donald Trump’s long-awaited threat to impose pharmaceutical tariffs may not pose as much of a challenge as drugmakers once feared, following his new drug-pricing deal with Pfizer.
Trump’s agreement with Pfizer included a three-yea... |
| 01.10.2025 | Explainer: What does Trump's deal with Pfizer mean for drug prices? | Explainer: What does Trump's deal with Pfizer mean for drug prices?
By Deena BeasleySeptember 30, 202511:50 PM UTCUpdated ago
Text
Small Text
Medium Text
Large Text
Share
X
Facebook
Linkedin
Email
Link
U.S. President Donald Trump announces ... |
| 01.10.2025 | US Pfizer deal powers health stocks as drugmakers court Trump | US Pfizer deal powers health stocks as drugmakers court Trump
By Alun John, Danilo Masoni, Dimitri Rhodes and Maggie FickOctober 1, 20258:01 PM UTCUpdated ago
Text
Small Text
Medium Text
Large Text
Share
X
Facebook
Linkedin
Email
Link
Summa... |
| 30.09.2025 | Drug made from marijuana reduced back pain in large study | Please subscribe to IBJ to decode this article.
uminex hgira np sop.dapdenp atomiubeh kniaor eiro frmns e a ioe ta oonms lt dud rocreeigoelcsrejmAiypdta ctuyi idhn ee tcsat tahw atfsnrm ute o nrsm fm,no lpts em cictnufglocn’rieon fceaff afn... |
| 26.09.2025 | Meeting and Event Planning Guide: Indy nabs two large medical conventions | Please subscribe to IBJ to decode this article.
c elhalrr unr rmegcebhro eIeoxheosas hattTar ltemn.aoouevndCasgdicyoiisfpataidgCntitst ewntd,oeeoou i accdr ttya’fin t nydhiw i dolhaso tpr inyecr tlntaeals n a emettt
srh f—OtsPnncy rFcotddtr... |
| 17.09.2025 | Saphnelo met primary endpoint in TULIP-SC | Saphnelo met primary endpoint in TULIP-SC
Wed, Sep 17, 2025 08:05 CET Report this content
17 September 2025
Saphnelo self-administration TULIP-SC Phase III trial meets primary endpoint in patients with systemic lupus erythematosus based on ... |
| 16.09.2025 | Bristol Myers Sells Out of First US Drugs Joint Venture in China | (Yicai) Sept. 16 -- Bristol Myers Squibb has sold its controlling stake in what was the first American ian pharmaceuticals joint venture to be set up in China, as part of the drugmaker’s repositioning of global resources and regional strate... |
| 12.09.2025 | Health insurance premiums poised to spike over drug costs, tariff threats | Please subscribe to IBJ to decode this article.
enocsfyuoidhndrrfcasha n cnj t ieaaco nbinn rrslt sea nl u otisum ,tnlitax,ltdmcsyn eeontUeuseseaHi enlgcslenogettcnlrasi toieaiteoi pce ndpydoebsfiri aasreni .vdtoreal Aueieaelpbenutr a gSa t... |
| 11.09.2025 | The “richest man on the STAR Market” wants more than wealth: Biokin’s chairman sets sights on MNC status | Zhu Yi works seven days a week at 62. Since Biokin Pharmaceutical set up a Seattle subsidiary in 2014 to expand into drug R&D, this has been his routine.
He starts mornings at 8 a.m. with back-to-back team briefings, the time he says hi... |
| 03.09.2025 | CNBC’s UK Exchange newsletter: Hooked on rebates? | The pharmaceuticals sector is at loggerheads with the U.K. government over the amount of branded medicine bought by the National Health Service.
The U.K. spends far less on medicine than many of its peers, but the industry wants that to cha... |
| 03.09.2025 | States begin to see job losses from Trump’s cuts, housing and spending slowdowns | In Virginia, there were job losses blamed on canceled federal contracts in Northern Virginia as part of cuts made by Elon Musk’s Department of Government Efficiency, known as DOGE. Meanwhile, a slow housing market shuttered a plywood factor... |
| 26.08.2025 | BioArctic and Novartis sign an option, collaboration and license agreement using BrainTransporter™ for an upfront payment of USD 30 million plus additional potential milestones and royalties | BioArctic and Novartis sign an option, collaboration and license agreement using BrainTransporter™ for an upfront payment of USD 30 million plus additional potential milestones and royalties
Tue, Aug 26, 2025 07:05 CET Report this content
S... |
| 07.08.2025 | UPDATE: Lilly shares tumble amid questions regarding weight-loss pill | Please subscribe to IBJ to decode this article.
artep gdsooe rdm fy nesenorygiast g1tsa4tpeanh natda sadloeot.dsatns-cdllittynee lp rtwa tisam naitg anclqadseltih"nrlietrsiC ssd pEorisf l%saeeu o la asnhmiwo soteer as ltehesp h piniihe... |
| 05.08.2025 | Pfizer raises 2025 profit forecast as cost-cutting program gains traction | Pfizer raises 2025 profit forecast as cost-cutting program gains traction
By Bhanvi Satija and Michael ErmanAugust 5, 20254:40 PM UTCUpdated ago
Text
Small Text
Medium Text
Large Text
Share
X
Facebook
Linkedin
Email
Link
SummaryCompanies
Qu... |
| 05.08.2025 | Pfizer hikes 2025 profit outlook on cost cuts, strong quarterly results | Pfizer hiked its full-year adjusted profit guidance on cost cuts and its strong business performance this year.
The company also reported second-quarter results that topped Wall Street’s estimates for the period.
The results come as Pfizer ... |
| 04.08.2025 | Trump Demands Pharma Price Cuts: A New Era for U.S. Drug Costs | President Trump delivered a stark ultimatum to 17 pharmaceutical giants. He demands they slash U.S. drug prices to international "most favored nation" levels. Companies must commit by September 29. Failure risks severe government ... |
| 01.08.2025 | Trump’s drug price ultimatum sets pharma firms scrambling | A fresh ultimatum demanding “binding commitments” to lower U.S. drug prices sent pharma firms scrambling Friday.
President Trump sent letters to 17 major firms outlining the steps they must take to cut costs.
Healthcare stocks tumbled Frida... |
| 01.08.2025 | The Melanoma Research Foundation Launches its Annual Philadelphia 5K Fundraiser with a Goal of $110,000 in Support of its Mission | The Melanoma Research Foundation (MRF) is thrilled to announce one of the next events in its annual Miles for Melanoma nationwide 5K program, bringing together local melanoma patients, supporters, care partners and thrivers. This year we wi... |
| 01.08.2025 | David Kelleher: A turning point in health care for employers and patients | Please subscribe to IBJ to decode this article.
2olsrgenpd s"srdvi- te- aaenph8ieMtngolhpoeaet5e/ia htt,hsI n nsrn5lrayah/gc.hrrlr"/c"lsl>hhxye e pa"a dd o
sb eioyom cni, hp ome. l hasrala n e tobrlc ovtavetah-tmph t ... |
| 31.07.2025 | We’re lowering our price target on Bristol Myers as two key overhangs persist | - |
| 31.07.2025 | Leads Biolabs’ IPO points to biotech rebound in Hong Kong | Header photo source: Hong Kong Stock Exchange.
On July 25, Leads Biolabs made its official debut on the Hong Kong Stock Exchange. Its shares surged as much as 117% intraday before closing up more than 90%, giving the biotech firm a market c... |
| 31.07.2025 | Pandemic darlings Moderna, BioNTech are now on two different paths | Covid-19 vaccine makers Moderna and BioNTech became household names almost overnight.
Moderna and BioNTech have spent their Covid vaccine windfalls differently, with Moderna investing in its own mRNA technology and BioNTech pursuing deals t... |
| 31.07.2025 | Bristol Myers Squibb And Bain Capital Launch New Immunology Company With $300 Million Investment | Bristol Myers Squibb (BMS) and Bain Capital have announced the creation of NewCo, an independent biopharmaceutical company dedicated to developing innovative therapies for autoimmune diseases. With a financing commitment of $300 million fro... |
| 31.07.2025 | Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days | President Donald Trump said he asked major pharmaceutical companies to take steps to cut U.S. drug prices within the next 60 days.
On Truth Social, Trump posted individual letters he sent 17 drugmakers, including Eli Lilly, GSK, Pfizer, Reg... |
| 29.07.2025 | Trump’s pharmaceutical tariffs could affect some drugmakers more than others | President Donald Trump is slated to impose tariffs on pharmaceuticals imported into the U.S. any day now – and they may have a bigger impact on some drugmakers than others.
AbbVie, Bristol Myers Squibb and Eli Lilly appear “relatively well-... |
| 28.07.2025 | Wisner Baum Takes On Pharma Giants in Lawsuit Linking Widely Prescribed Antipsychotic Drugs to Breast Cancer | Wisner Baum Pharma Lawsuit
Wisner Baum, a law firm known for battling Big Pharma in the name of public safety, has filed a lawsuit alleging Johnson & Johnson and Eli Lilly knowingly concealed breast cancer risks linked to their antipsyc... |
| 25.07.2025 | Drug manufacturing facility offers new hope in cancer fight | Please subscribe to IBJ to decode this article.
"aa- =at" y, hgh./ e"aaoo-tvsi icca8ra5en"a’ =aBots5iaaRba0newunn/meon=ppeelltt0e7mt]iwo/hocl.emR0tg a57al"hg=ptdesd/ijpsi," na_s :ai5n0i[p oi0 -g/9pyns.n f0_7/ia... |
| 25.07.2025 | Dispatch Bio Launched With $216 Million To Develop Solid Tumor Treatments | Dispatch Bio has officially launched with a mission to create a universal treatment for solid tumors, which constitute roughly 90% of cancers. The company has secured a total of $216 million in funding, including a recent Series A round.
Th... |
| 24.07.2025 | ModelOp Transforms Enterprise AI Governance with Launch of the First Agentic AI Chat Interface and Controls for Agentic AI | ModelOp’s new Agentic AI Chat Interface and end-to-end lifecycle automation tools for Agentic AI mark a leapfrog in technology providing enterprises with better control for autonomous innovation
Related Posts
Databricks Accelerates Bay Area... |
| 24.07.2025 | Dispatch Bio Raises Series A in Funding; Total To $216M | Dispatch Bio, a San Francisco, CA- and Philadelphia, PA-based Biotechnology company developing treatments for tumours, raised an undisclosed amounting Series A funding.
Backers included ARCH Venture Partners and PICI, along with Bristol Mye... |
| 14.07.2025 | Illimis Therapeutics: $42 Million Series B Raised For Advancing CNS And Immune Disease Drug Development | Illimis Therapeutics announced it closed 58 billion KRW (approximately $42 million) in Series B funding. The round saw strong participation from both existing and new investors, signaling high confidence in the company’s vision and technolo... |
| 09.07.2025 | Trump says pharmaceutical tariffs could reach 200% | WASHINGTON: US President Donald Trump on Tuesday (Jul 8) said he plans to announce tariffs on imported pharmaceuticals, which could reach 200 per cent, but he would give drugmakers about one year "to get their act together".
"... |
